Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | ACP3 | P15309 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9261 | 1.00 | GSR (0.40) | GSRALDH1A1LMNANPC1ADAM17 | |
| SCHEMBL376375 | 0.79 | GSR (0.44) | GSRALDH1A1LMNANPC1ADAM17 | |
| SCHEMBL3125882 | 0.78 | GSR (0.41) | GSRALDH1A1LMNANPC1ADAM17 | |
| SCHEMBL2028620 | 0.78 | GSR (0.43) | GSRALDH1A1LMNANPC1ADAM17 | |
| SCHEMBL10403262 | 0.76 | GSR (0.55) | GSRALDH1A1LMNANPC1ADAM17 | |
| SCHEMBL10692142 | 0.76 | GSR (0.46) | GSRALDH1A1LMNANPC1ADAM17 | |
| SCHEMBL1831576 | 0.76 | GSR (0.42) | GSRALDH1A1LMNANPC1ADAM17 | |
| SCHEMBL10936620 | 0.76 | GSR (0.42) | GSRALDH1A1LMNANPC1ADAM17 | |
| SCHEMBL8582412 | 0.76 | GSR (0.42) | GSRALDH1A1LMNANPC1ADAM17 | |
| SCHEMBL27521461 | 0.76 | GSR (0.46) | GSRALDH1A1LMNANPC1ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118076628-A | Activatable cytokine constructs and related compositions and methods | 西托姆克斯治疗公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-118076627-A | Trimeric activatable cytokine constructs and related compositions and methods | 西托姆克斯治疗公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-118043064-A | Activatable cytokine constructs and methods of combination | 西托姆克斯治疗公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240124546-A1 | MASKED ACTIVATABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHOD | CYTOMX THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | US | disclosed |
| WO-2024030843-A1 | PROTEASE-CLEAVABLE MOIETIES AND METHODS OF USE THEREOF | CYTOMX THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024030850-A1 | PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF | CYTOMX THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024030847-A1 | PROTEASE-CLEAVABLE MOIETIES AND METHODS OF USE THEREOF | CYTOMX THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024030858-A1 | PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF | CYTOMX THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024030845-A1 | PROTEASE-CLEAVABLE MOIETIES AND METHODS OF USE THEREOF | CYTOMX THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| EP-4308594-A2 | MASKED ACTIVATABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS | CytomX Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20230192798-A1 | ACTIVATABLE CYTOKINE CONSTRUCTS AND COMBINATION METHODS | CYTOMX THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-11667687-B2 | Masked activatable interferon constructs | CYTOMX THERAPEUTICS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230057263-A1 | SINGLE-AND MULTI-CHAIN POLYPEPTIDES THAT BIND SPECIFICALLY TO CD3 EPSILON | CYTOMX THERAPEUTICS, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| EP-4133085-A1 | ACTIVATABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS | CytomX Therapeutics, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| CN-115667523-A | Activatable cytokine constructs and related compositions and methods | 西托姆克斯治疗公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20220402990-A1 | ACTIVATABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS | CYTOMX THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | US | disclosed |
| US-11365233-B2 | Activatable cytokine constructs and related compositions and methods | CYTOMX THERAPEUTICS, INC. (US) | 2022-06-21 | — | — | US | disclosed |
| US-20210317177-A1 | ACTIVATABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS | CYTOMX THERAPEUTICS, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| EP-1242372-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001046138-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |